BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 38632528)

  • 1. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.
    Liu X; Li S; Ke L; Cui H
    BMC Cancer; 2024 Apr; 24(1):490. PubMed ID: 38632528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
    Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
    Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current understanding of CTLA-4: from mechanism to autoimmune diseases.
    Hossen MM; Ma Y; Yin Z; Xia Y; Du J; Huang JY; Huang JJ; Zou L; Ye Z; Huang Z
    Front Immunol; 2023; 14():1198365. PubMed ID: 37497212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis.
    Cai Q; Huo GW; Zhu FY; Yue P; Yuan DQ; Chen P
    Hum Vaccin Immunother; 2022 Dec; 18(7):2145102. PubMed ID: 36471629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
    Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
    BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.
    Panhaleux M; Espitia O; Terrier B; Manson G; Maria A; Humbert S; Godbert B; Perrin J; Achille A; Arrondeau J; Kostine M; Fallet V; Pugnet G; Chaigne B; Champiat S; Laparra A; Danlos FX; Launay D; Penel N; Lambotte O; Michot JM; Forestier A
    Eur J Cancer; 2022 Jan; 160():134-139. PubMed ID: 34810048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between
    Zhou C; Gao S; Yuan X; Shu Z; Li S; Sun X; Xiao J; Liu H
    Aging (Albany NY); 2021 Aug; 13(15):19397-19414. PubMed ID: 34339393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis.
    Yamaguchi A; Saito Y; Okamoto K; Narumi K; Furugen A; Takekuma Y; Sugawara M; Kobayashi M
    Support Care Cancer; 2021 Dec; 29(12):7747-7753. PubMed ID: 34164739
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.